New hope for rare bone disease pain?
NCT ID NCT01791842
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a drug called tocilizumab for people with fibrous dysplasia of bone who still had pain after standard treatment. The drug blocks a protein linked to bone breakdown. Nineteen adults participated in this small, early-stage trial to see if the drug could reduce bone pain and slow bone damage.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FIBROUS DYSPLASIA OF BONE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Service de Rhumatologie, Groupe Hospitalier Pellegrin
Bordeaux, France
-
Service de rhumatologie, Hopital Edouard Herriot, HCL
Lyon, 69003, France
-
Service de rhumatologie, Hôpital Lariboisière
Paris, 75010, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.